Moray Gökhan, Tezcaner Tugan, Özçay Figen, Baskın Esra, Akdur Aydıncan, Kırnap Mahir, Yıldırım Sedat, Arslan Gülnaz, Haberal Mehmet
From the Department of General Surgery, Baskent University, School of Medicine, Ankara, Turkey.
Exp Clin Transplant. 2015 Apr;13 Suppl 1:145-7.
Primary hyperoxaluria, especially type 1, is a severe disease with multisystem morbidity and high mortality. We present 3 primary hyperoxaluria type 1 patients who underwent liver transplant, including living-donor liver transplant or combined liver and kidney transplant in our institution.
Patients who underwent liver transplant or combined liver/kidney transplant at our institution were evaluated, retrospectively. Between January 2002 and 2013, there were 3 patients who underwent transplant for primary hyperoxaluria. All 3 patients had disease onset in childhood, and the definitive diagnosis was established at age < 1, 6, and 8 years. Although early diagnosis was made, primary hyperoxaluria resulted in end-stage renal disease in 2 patients, and hemodialysis was introduced before liver transplant. All 3 patients underwent living-donor liver transplant. Case 1 was a 10-year-old girl who had an uneventful course after living-donor liver transplant, and she received a living-donor kidney transplant from the same donor 4 months after living-donor liver transplant. Case 2 was a 7-yearold boy who was the younger brother of the first patient; he did not have end-stage renal disease or any renal disorder after successful living-donor liver transplant. Case 3 was a 3-year-old boy who was diagnosed at age 2 months with renal disorders; although he was discharged from the hospital after living-donor liver transplant, he was readmitted because of unconsciousness that developed 1 day after discharge, and he died because of intracranial hemorrhage 2 months after liver transplant, unable to receive a kidney transplant.
Primary hyperoxaluria is a rare disorder that is difficult to diagnose until end-organ damage is severe. Outcomes may be improved with early and accurate diagnosis, aggressive supportive treatment, and correction of the enzyme defect by liver transplant before systemic oxalosis develops. However, kidney transplant or combined liver and kidney transplant is required in many primary hyperoxaluria type 1 patients because of the delayed diagnosis or long organ waiting time.
原发性高草酸尿症,尤其是1型,是一种严重疾病,具有多系统发病且死亡率高。我们报告了3例在我院接受肝移植的1型原发性高草酸尿症患者,包括活体供肝移植或肝肾联合移植。
对在我院接受肝移植或肝肾联合移植的患者进行回顾性评估。2002年1月至2013年期间,有3例患者因原发性高草酸尿症接受移植。所有3例患者均在儿童期发病,确诊年龄分别为<1岁、6岁和8岁。尽管诊断较早,但原发性高草酸尿症导致2例患者出现终末期肾病,并在肝移植前开始进行血液透析。所有3例患者均接受了活体供肝移植。病例1是一名10岁女孩,活体供肝移植后病情平稳,在活体供肝移植4个月后从同一供体接受了活体供肾移植。病例2是一名7岁男孩,是首例患者的弟弟;成功进行活体供肝移植后,他未出现终末期肾病或任何肾脏疾病。病例3是一名3岁男孩,2个月大时被诊断患有肾脏疾病;尽管活体供肝移植后出院,但出院1天后因意识不清再次入院,肝移植2个月后因颅内出血死亡,未能接受肾移植。
原发性高草酸尿症是一种罕见疾病,在终末器官损害严重之前难以诊断。早期准确诊断、积极的支持治疗以及在全身草酸osis发生之前通过肝移植纠正酶缺陷可能会改善预后。然而,由于诊断延迟或器官等待时间长,许多1型原发性高草酸尿症患者需要进行肾移植或肝肾联合移植。